Korro Bio (NASDAQ:KRRO) Given “Overweight” Rating at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Korro Bio (NASDAQ:KRRO) in a research report released on Wednesday, Benzinga reports. They currently have a $180.00 price target on the stock.

Other research analysts also recently issued reports about the company. BMO Capital Markets restated an outperform rating and issued a $120.00 price target on shares of Korro Bio in a research note on Tuesday. HC Wainwright restated a buy rating and issued a $100.00 price target on shares of Korro Bio in a research note on Friday, January 19th. Finally, Royal Bank of Canada upped their price target on Korro Bio from $70.00 to $90.00 and gave the stock an outperform rating in a research note on Wednesday.

Korro Bio Stock Up 1.8 %

KRRO stock opened at $88.53 on Wednesday. Korro Bio has a 1-year low of $9.15 and a 1-year high of $97.91. The company has a market cap of $65.51 million, a P/E ratio of -0.94 and a beta of 2.09. The business has a 50 day simple moving average of $54.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. North Star Investment Management Corp. bought a new position in shares of Korro Bio during the 4th quarter valued at approximately $48,000. Tower Research Capital LLC TRC bought a new position in shares of Korro Bio during the 4th quarter valued at approximately $190,000. Northern Trust Corp bought a new position in shares of Korro Bio during the 4th quarter valued at approximately $504,000. Verition Fund Management LLC bought a new position in shares of Korro Bio during the 4th quarter valued at approximately $2,784,000. Finally, Monashee Investment Management LLC bought a new position in shares of Korro Bio during the 4th quarter valued at approximately $4,352,000. 13.18% of the stock is currently owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.